Clinical Trials
18 trialsNCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT05286814 2026-05-04
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03370718 2024-12-10
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03612232 2024-08-19
CaboACC
Wuerzburg University Hospital
Phase 2 Unknown
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
NCT02468193 2020-05-06
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Novartis
Phase 2 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT02720484 2019-05-01
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
Northwestern University
Phase 2 Terminated
NCT00215202 2018-05-17
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00936741 2014-04-02
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Corcept Therapeutics
Phase 3 Completed
NCT00569582 2013-08-22
SEISMIC
Corcept Therapeutics
Phase 3 Completed
NCT01255137 2013-06-27
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00071058 2012-09-18
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed